| Date | Title | Description |
| 06.04.2026 | Aurobindo Pharma board approves ₹800 crore share buyback | - |
| 04.04.2026 | India’s pharma exports grow 5.6% to $28 billion in April–February FY26 | - |
| 27.03.2026 | Activist Investor Elliott Targets Chip Design Giant Synopsys | Activist investor Elliott Management now holds a multibillion-dollar stake in Synopsys. This investment targets improved financial performance. Synopsys develops essential software for global chip design, crucial for AI innovation. Nvidia r... |
| 27.03.2026 | Indian Innovation Surges: Biotech, AI, EdTech Secure Major Funding | Indian startups attract significant capital. Elmed Life Sciences raised $2.7M for advanced probiotic solutions in health and agriculture. Deccan AI secured $25M, boosting enterprise AI deployments. Edtech firm Qweebi gained $500K for K-12 S... |
| 26.03.2026 | Elmed Life Sciences raises $2.7 million from Nabard-backed Agrisure Fund | Synopsis
Elmed Life Sciences has raised $2.7 million from Agrisure Fund, which is managed by Nabard-backed Nabventures. The company develops and manufactures probiotic and biological solutions for animal health, aquaculture, agriculture, an... |
| 23.03.2026 | Activist Elliott takes multibillion-dollar stake in Synopsys, source says | Synopsis
Sunnyvale, California-based Synopsys, valued at over $80 billion, has for decades been one of the main suppliers of software used in determining how âto arrange â the â tens of billions of transistors that make up chips from fi... |
| 12.03.2026 | Aurobindo unit gets VAI classification from USFDA for Andhra plant | - |
| 22.02.2026 | Expects Pen-G production capacity to touch 10k metric tonnes in 12 months: Aurobindo Pharma | - |
| 25.12.2025 | Kargo Secures $42 Million to Revolutionize Supply Chain with AI Automation | Kargo secures $42M Series B funding, led by Avenir. The AI firm rapidly scales its smart loading dock and warehouse technology. This automates freight inspection, verification, and real-time data flow for global logistics. Kargo’s revenue t... |
| 23.12.2025 | Kargo: $42 Million Series B Raised To Expand AI-Powered Warehouse Deployments | Kargo, an industrial artificial intelligence company focused on supply chain and logistics, has raised a $42 million Series B funding round as it looks to scale deployments of its warehouse and loading dock technology with large enterprise ... |
| 23.10.2025 | Aurobindo Pharma expands footprint in South America with new subsidiary in Chile | - |
| 11.09.2025 | GTCR покупает чешского производителя дженериков Zentiva у Advent International за $4,8 млрд | Фирма прямых инвестиций GTCR заключила сделку на 4,1 млрд евро ($4,8 млрд) о покупке чешского производителя дженериковых лекарств Zentiva у Advent International, сообщил в среду Financial Times со ссылкой на неназванные источники.
Reuters н... |
| 21.08.2025 | Aurobindo Pharma set to tap biosimilars revenue in Europe | - |
| 13.08.2025 | Cronus Pharma draws PE interest four years after failed Aurobindo deal | Pro
Credit: Pexels
Cronus Pharma, an animal healthcare company that top Indian drugmaker Aurobindo Pharma wanted to acquire in 2021 before cancelling the deal, has now attracted interest from a few private equity investors, two people famil... |
| 04.08.2025 | Aurobindo Pharma’s Q1 net down 10.2% at ₹824 cr | - |
| 27.06.2025 | Aurobindo Pharma recalls 4,608 bottles of pain relieving drug in US | - |
| 05.06.2025 | Medical Biotechnology in the Age of Personalised Medicine: Preparing Scientists for the Future of Healthcare | Chittoor, Andhra Pradesh, India
We are in an age where medicine is no longer one-size-fits-all; personalised healthcare is changing the diagnosis and treatment of diseases. Ranging from gene editing to precision diagnostics, the future of m... |
| 16.05.2025 | Aurobindo Pharma’s arm teams up with IMT Hyderabad for leadership development | - |
| 16.02.2025 | Aurobindo Pharma to commence supplies to Europe from China plant in April | Aurobindo Pharma will commence supplies to Europe from its China facility from April onwards, according to Chief Financial Officer Santhanam Subramanian.
The Hyderabad-based drug maker commenced operations at the facility in the last week o... |
| 07.02.2025 | Morning Bid: India eyes historic rate cut, global easing momentum mounts | Morning Bid: India eyes historic rate cut, global easing momentum mounts
By Jamie McGeeverFebruary 6, 20259:46 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Commentary
A Reserve Bank of India ... |
| 15.12.2024 | Aurobindo, Glenmark, Zydus recall products in US over manufacturing issues | Drug makers Aurobindo Pharma, Glenmark and Zydus are recalling products in the US market due to manufacturing issues, according to the US health regulator.
As per the latest Enforcement Report of US Food and Drug Administration (USFDA), Aur... |
| 06.12.2024 | Orchid’s new division targets knowledge partner positioning to drive AMR solutions | Orchid Pharma Ltd’s newly launched Antimicrobial Solutions (AMS) division is focusing on positioning itself as a knowledge partner, not just a supplier. This approach is designed to differentiate the company in the highly competitive and re... |
| 12.11.2024 | CuraTeQ Biologics’ Hydrogen plant gets GMP certificate from EMA | CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received a Good Manufacturing Practice (GMP) certificate of compliance for its biosimilars manufacturing facility from the EMA.
The GMP inspection, conducted by EMA repre... |
| 16.08.2024 | USFDA issues warning letter to Aurobindo arm Eugia Pharma | A formulation manufacturing facility of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, received a warning letter from the US Food and Drug Regulator (USFDA).
The Hyderabad-based Aurobindo, earlier said, the unit I... |
| 03.06.2024 | Aurobindo Pharma secures marketing authorisation for Trastuzumab biosimilar in India | Aurobindo received its first marketing authorisation for the biosimilar drug trastuzumab, which is used for breast cancer treatment, in the Indian market in the current financial year.
“We have promptly applied for a manufacturing license. ... |
| 31.05.2024 | Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing | - |
| 29.05.2024 | Health secy highlights India's achievements, future goals at WHO assembly | - |
| 27.05.2024 | Indian pharmaceutical companies likely to cash in on US drug shortages | - |
| 25.05.2024 | Aurobindo Pharma Q4 PAT up by 79% at ₹909 crore | Aurobindo Pharma has reported a net profit of ₹909 crore in the fourth quarter ending March 31, 2024, as against ₹506 crore in the same quarter last year, showing a growth of 79.6 per cent.
The company registered a revenue of ₹7,580 crore i... |
| 24.05.2024 | Weak Q4 due to lower growth may be rare bitter pill for Sun Pharma | - |
| 22.05.2024 | Sun Pharma Q4 net profit up 34 per cent, on strong global speciality business | Sun Pharmaceutical Industries has reported a net profit of ₹2,654 crore for the three months ended March 31, 2024, up 34 per cent as compared to ₹1,984 crore in the same period last year. It posted gross sales of ₹11,813 crore, up 10.1 per ... |
| 21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
| 19.05.2024 | Dr Reddy's, Sun Pharma, Aurobindo recall products in the US | Drug makers Dr Reddy's Laboratories, Sun Pharma and Aurobindo Pharma are recalling products in the US market due to manufacturing issues, as per the latest Enforcement Report of the US Food and Drug Administration (USFDA).
Dr Reddy's Labora... |
| 17.05.2024 | Indian pharma firms supplied 47% of all generic prescriptions in US in 2022 | - |
| 08.05.2024 | Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings | - |
| 06.05.2024 | Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results | - |
| 04.05.2024 | Aurobindo Pharma Hit with ₹13 Crore Tax Demand | Aurobindo Pharma Ltd. faces a hefty tax demand of over ₹13 crore, including interest and penalties, from the GST authority. The demand stems from an ineligible input tax credit claim, according to the Deputy Commissioner of GST in Hyderabad... |
| 04.05.2024 | Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study | - |
| 04.05.2024 | India raises issue of pharma pricing control in Australia on generic drugs | - |
| 03.05.2024 | Aurobindo Pharma gets tax demand of ₹13 crore, including interest and penalties | Aurobindo Pharma Ltd. said on Friday it has received a tax demand of over ₹13 crore, including interest and penalty, from the GST authority over an ineligible input tax credit claim.
Also read: Aurobindo Pharma Q3 net up 17% at ₹836 crore
T... |
| 03.05.2024 | Aurobindo Pharma gets tax demand of over Rs 13 cr from Hyderabad officials | - |
| 02.05.2024 | India, New Zealand look to boost collaboration in pharma, digital trade | - |
| 01.05.2024 | Mizoram sees alarming surge in TB deaths, 108 succumb to disease in 2023 | - |
| 01.04.2024 | NTPC adds nearly 4GW capacity in FY24; total installed capacity at 76GW | State-run power giant NTPC on Monday said it has added 3,924 MW power generation capacity in 2023-24, taking the total installed capacity to around 76GW.
This (3,924 MW) includes the commissioning of the second unit in Bangladesh and maiden... |
| 01.04.2024 | Toyota Kirloskar sees highest-ever monthly sales at 27,180 units in March | Toyota Kirloskar Motor on Monday reported its highest-ever monthly wholesales at 27,180 units in March.
The company's total dispatches to dealers increased 25 per cent last month to 22,910 units as compared with 21,783 units in March 2023.
... |
| 01.04.2024 | Aurobindo Pharma commissions 4 plants in Andhra including Pen-G facility | Aurobindo Pharma on Monday said it has commissioned four state-of-the-art manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries.
Penicillin-G... |
| 14.03.2024 | Pharma regulation: A complex problem | Many consumer goods contain an asymmetric information problem. It is unreasonable to think that a consumer will run tests and verify the purity and soundness of a product, especially in the case of food and drugs. As an example, on March 13... |
| 02.04.2020 | Novartis cancels $1B sale of generics after antitrust concerns forced delays | Novartis has scrapped a generics sale that could have netted $1 billion after failing to obtain approval from the Federal Trade Commission on time.
CEO Vas Narasimhan first announced the deal to sell 300 products from Sandoz... |
